Table 2.
Clinicopathological Characteristics of 70 NSCLC Patients Stratified by the PD-L1 Polymorphisms rs4742098, rs4143815, rs2297136 and rs7041009
| Characteristics | rs4742098 AA vs AG/GG | rs4143815 GG vs CG/CC | rs2297136 GG vs AG/AA | rs7041009 GG vs AG/AA | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of Patients (N=70) (%) | No. of Patients (N=70) (%) | No. of Patients (N=70) (%) | No. of Patients (N=70) (%) | |||||||||
| A/A | A/G+G/G | P | G/G | C/G+C/C | P | G/G | AG+A/A | P | G/G | A/G+A/A | P | |
| Age (years), median | ||||||||||||
| ≤ 63 | 13 (56.5%) | 10 (62.5%) | 0.75 | 11 (57.9%) | 12 (60.0%) | 1.00 | 4 (57.1%) | 19 (59.4%) | 1.00 | 16 (76.2%) | 7 (38.9%) | 0.02 |
| >63 | 10 (43.5%) | 6 (37.5%) | 8 (42.1%) | 8 (40.0%) | 3 (42.9%) | 13 (40.6%) | 5 (23.8%) | 11 (61.1%) | ||||
| Gender, n (%) | ||||||||||||
| Male | 13 (56.5%) | 11 (64.7%) | 0.74 | 12 (63.2%) | 12 (57.1%) | 0.75 | 4 (57.1%) | 20 (60.6%) | 1.00 | 12 (57.1%) | 12 (63.2%) | 0.75 |
| Female | 10 (43.5%) | 6 (35.3%) | 7 (36.8%) | 9 (42.9%) | 3 (42.9%) | 13 (39.4%) | 9 (42.9%) | 7 (36.8%) | ||||
| Smoke status | ||||||||||||
| Yes | 10 (71.4%) | 9 (75.0%) | 1.00 | 9 (75.0%) | 10 (71.4%) | 1.00 | 4 (66.7%) | 15 (75.0%) | 1.00 | 9 (60.0%) | 10 (90.9%) | 0.17 |
| No | 4 (28.6%) | 3 (25.0%) | 3 (25.0%) | 4 (28.6%) | 2 (33.3%) | 5 (25.0%) | 6 (40.0%) | 1 (9.1%) | ||||
| Histology | ||||||||||||
| ADC | 18 (43.9%) | 15 (51.7%) | 0.61 | 15 (41.7%) | 18 (52.9%) | 0.40 | 7 (53.8%) | 26 (45.6%) | 0.86 | 15 (41.7%) | 18 (55.9%) | 0.34 |
| SqCC | 16 (39.0%) | 8 (27.6%) | 15 (41.7%) | 9 (26.5%) | 4 (30.8%) | 20 (35.1%) | 12 (33.3%) | 12 (35.3%) | ||||
| LCC | 7 (17.1%) | 6 (20.7%) | 6 (16.7%) | 7 (20.6%) | 2 (15.4%) | 11 (16.3%) | 9 (25.0%) | 4 (11.8%) | ||||
| Clinical stage† | ||||||||||||
| I–II | 8 (40.0%) | 7 (50.0%) | 0.72 | 7 (41.2%) | 8 (47.1%) | 1.00 | 1 (14.3%) | 14 (51.9%) | 0.10 | 8 (44.4%) | 7 (43.8%) | 1.00 |
| III–IV | 12 (60.0%) | 7 (50.0%) | 10 (58.8%) | 9 (52.9%) | 6 (85.7%) | 13 (48.1%) | 10 (55.6%) | 9 (56.3%) | ||||
| Mcs+PD-L1 (median) | ||||||||||||
| ≤1.26 | 15 (57.7%) | 11 (42.3%) | 0.78 | 14 (53.8%) | 12 (46.2%) | 1.00 | 6 (23.1%) | 20 (76.9%) | 0.74 | 11 (42.3%) | 15 (57.7%) | 0.27 |
| >1.26 | 14 (51.9%) | 13 (48.1%) | 14 (51.9%) | 13 (48.1%) | 5 (18.5%) | 22 (81.5%) | 16 (59.3%) | 11 (40.7%) | ||||
| Chemotherapy | ||||||||||||
| Yes | 7 (30.4%) | 7 (41.2%) | 0.52 | 5 (26.3%) | 9 (42.9%) | 0.33 | 3 (42.9%) | 11 (33.3%) | 0.67 | 10 (47.6%) | 4 (21.1%) | 0.10 |
| No | 16 (69.6%) | 10 (58.8%) | 14 (73.7%) | 12 (57.1%) | 4 (57.1%) | 22 (66.7%) | 11 (52.4%) | 15 (78.9%) | ||||
| Radiotherapy | ||||||||||||
| Yes | 1 (4.3%) | 1 (5.9%) | 1.00 | 1 (5.3%) | 1 (4.8%) | 1.00 | 1 (14.3%) | 1 (3.00%) | 0.32 | 0 (0.0%) | 2 (10.5%) | 0.21 |
| No | 22 (95.7%) | 16 (94.1%) | 18 (94.7%) | 20 (95.2%) | 6 (85.7%) | 32 (97.0%) | 21 (100.0%) | 17 (89.5%) | ||||
| Relapse | ||||||||||||
| Yes | 11 (78.6%) | 4 (28.6%) | 0.01 | 9 (75.0%) | 6 (37.5%) | 0.05 | 5 (71.4%) | 10 (47.6%) | 0.39 | 5 (33.3%) | 10 (76.9%) | 0.02 |
| No | 3 (21.4%) | 10 (71.4%) | 3 (25.0%) | 10 (62.5%) | 2 (28.6%) | 11 (52.4%) | 10 (66.7%) | 3 (23.1%) | ||||
| Status | ||||||||||||
| Live | 5 (38.5%) | 8 (53.3%) | 0.47 | 5 (45.5%) | 8 (47.1%) | 1.00 | 3 (50.0%) | 10 (45.5%) | 1.00 | 11 (78.6%) | 2 (14.3%) | 0.00 |
| Dead | 8 (61.5%) | 7 (46.7%) | 6 (54.5%) | 9 (52.9%) | 3 (50.0%) | 12 (54.5%) | 3 (21.4%) | 12 (85.7%) | ||||
Notes: Bolded values are statically significant. †8th International Association for the Study of Lung Cancer [23].
Abbreviations: ADC, adenocarcinoma; SqCC, squamous cell carcinoma; LCC, large cell carcinoma; Mcs, malignant cells; PD-L1, programmed death-ligand 1.